Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04501874 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
A Phase 2 study, sponsored by Embera NeuroTherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT04501874 is a Phase 2 study that has completed, run by Embera NeuroTherapeutics. The registered enrollment target is 82 participants.
The verdict
NCT04501874, a Phase 2 study, has completed, sponsored by Embera NeuroTherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine Use Disorder (CUD).
Interventions
- DRUG EMB-001
- DRUG EMB-001 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2022-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04501874
The ClinicalTrials.gov registry entry for NCT04501874 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Embera NeuroTherapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EMB-001 is the first listed.
NCT04501874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04501874 about?
NCT04501874 is a clinical study titled "A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder". EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This is a Phase 2 study in approximately 80 adult subjects with moderate-to-sever...
What is the current status of trial NCT04501874?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2020-07-29. Estimated completion is 2022-10-15.
What interventions are being tested in trial NCT04501874?
The interventions under investigation include: EMB-001 (DRUG), EMB-001 Placebo (DRUG).
Who is sponsoring clinical trial NCT04501874?
This trial is sponsored by Embera NeuroTherapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.